Physician profile
Andrew Binamira
NPI 1952301939
$5,537.22
in general payments reported to CMS, 2019-2025
37 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $1,009 · 2021: $1,181 · 2022: $913 · 2023: $770 · 2024: $645 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $948.03 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $642.59 | 2021-2025 | Vraylar |
| Pfizer INC. | $568.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $486.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $465.90 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $460.25 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $286.26 | 2019-2022 | |
| Novo Nordisk INC | $270.17 | 2020-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $216.03 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $193.74 | 2019-2022 | |
| Lilly USA, LLC | $145.11 | 2020-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $122.80 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.60 | 2019-2024 | Xifaxan, Trulance |
| Vital Connect, INC | $92.23 | 2023 | Vitalpatch Rtm |
| Corcept Therapeutics | $43.17 | 2025 | Korlym |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Binamira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.